Dual-Tracer Theranostic PET
NCT05680675 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2025-02-06
Summary
This study is designed to obtain positron emission tomography with x-ray computed tomography (PET/CT) imaging data with each tracer pair, providing the imaging data needed to develop new simultaneous dual-tracer imaging techniques and processing algorithms for these tracer pairs.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Single-Tracer FDG PET/CT Exam
The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back "whole-body" (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
- DIAGNOSTIC_TEST
-
Single-Tracer Cu64-DOTATATE PET/CT Exam
The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back "whole-body" (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
- DIAGNOSTIC_TEST
-
Single-Tracer Ga68-DOTATATE PET/CT Exam
The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back "whole-body" (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
- DIAGNOSTIC_TEST
-
Single-Tracer PSMA PET/CT Exam
The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back "whole-body" (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
Sponsors & Collaborators
-
MultiFunctional Imaging LLC
collaborator UNKNOWN -
National Cancer Institute (NCI)
collaborator NIH - lead OTHER
Principal Investigators
-
Jeffrey A Yap, PhD · Huntsman Cancer Institute/ University of Utah
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-12-08
- Primary Completion
- 2024-06-04
- Completion
- 2024-06-04
Countries
- United States
Study Locations
More Related Trials
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
NCT06122610 ·Status: RECRUITING ·Phase: PHASE1
-
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
NCT07132645 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
NCT00282906 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
NCT02978586 ·Status: COMPLETED
-
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities
NCT04152928 ·Status: UNKNOWN ·Phase: NA
-
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
NCT03873870 ·Status: COMPLETED ·Phase: NA
-
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
NCT01557881 ·Status: TERMINATED ·Phase: NA
-
Energy CT in Imaging and Diagnosis of Gastric Cancer
NCT06869694 ·Status: RECRUITING
-
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
NCT03001349 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
NCT03271281 ·Status: COMPLETED ·Phase: PHASE2
-
Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT
NCT04622631 ·Status: UNKNOWN
-
Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients
NCT02245217 ·Status: COMPLETED ·Phase: NA
-
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
NCT03278275 ·Status: COMPLETED ·Phase: PHASE2
-
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
NCT04069299 ·Status: COMPLETED
-
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
NCT05737615 ·Status: WITHDRAWN ·Phase: PHASE1
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors
NCT07178587 ·Status: RECRUITING ·Phase: NA
-
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
NCT04525612 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
NCT05709171 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
NCT04017104 ·Status: UNKNOWN
-
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
NCT06690957 ·Status: RECRUITING
-
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
NCT04727632 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer
NCT02765698 ·Status: TERMINATED
-
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
NCT00362973 ·Status: COMPLETED
-
MPDL3280A-imaging-IST-UMCG
NCT02453984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA